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The goal of every form of drug delivery is achieving and maintaining a therapeutic time course of drug effect, while avoiding adverse effects. IV drugs are 
usually given using standard dosing guidelines. Typically 
the only patient covariate that is incorporated into a dose is 
a metric of patient size, typically weight for IV anesthetics. 
Patient characteristics such as age, sex, or creatinine clear-
ance are often not included because of the complex mathe-
matical relationship of these covariates to dose. Historically 
there have been 2 methods of administering IV drugs dur-
ing anesthesia: bolus dose and continuous infusion. Bolus 
doses are typically administered with a handheld syringe. 
Infusions are typically administered with an infusion pump.
Every anesthetic drug accumulates in tissue during drug 
delivery. This accumulation confounds the relationship 
between the infusion rate set by the clinician and the drug 
concentration in the patient. A propofol infusion rate of 100 
μg/kg/min is associated with a nearly awake patient 3 min-
utes into the infusion and a highly sedated or asleep patient 2 
hours later. By using well-understood pharmacokinetic (PK) 
principles, computers can calculate how much drug has accu-
mulated in tissues during infusions and can adjust the infu-
sion rate to maintain a stable concentration in the plasma or 
the tissue of interest, typically the brain. The computer is able 
to use the best model from the literature, because the math-
ematical complexity of incorporating patient characteristics 
(weight, height, age, sex, and additional biomarkers) are triv-
ial calculations for the computer.1,2 This is the basis of a third 
type of anesthetic drug delivery, target-controlled infusions 
(TCI). With TCI systems, the clinician enters a desired target 
concentration. The computer calculates the amount of drug, 
delivered as boluses and infusions, required to achieve the 
target concentration and directs an infusion pump to deliver 
the calculated bolus or infusion. The computer constantly 
calculates how much drug is in the tissue and exactly how 
that influences the amount of drug required to achieve the 
target concentration by using a model of the PKs of the drug 
selected and the patient covariates.
During surgery, the level of surgical stimulation can 
change very quickly, requiring precise, rapid titration of drug 
effect. Conventional infusions cannot increase drug concen-
trations rapidly enough to account for abrupt increases in 
stimulation or decrease concentrations rapidly enough to 
account for periods of low stimulation. Conventional infu-
sions cannot even maintain steady drug concentrations in 
the plasma or brain during periods of constant stimulation. 
By incorporating PK models, TCI systems can rapidly titrate 
response as necessary and similarly maintain steady concen-
trations when appropriate. The potential benefit to clinicians 
is the more precise titration of anesthetic drug effect.3
In this review, we describe the PK principles of TCI, the 
development of TCI systems, and technical and regulatory 
issues addressed in prototype development. Two accompa-
nying review articles cover the global use and safety issues 
related to this technology.4,5
As TCI systems evolved, investigators chose idio-
syncratic terms for the methodology. TCI systems have 
been referred to as computer-assisted total IV anesthesia 
(CATIA),6 titration of IV agents by computer (TIAC),7 com-
puter-assisted continuous infusion (CACI),8 and computer-
controlled infusion pump.9 Following a suggestion by Iain 
Glen, White and Kenny used the term TCI in their publica-
tions after 1992. A consensus was reached in 1997 among 
the active investigators that the term TCI be adopted as the 
generic description of the technology.10
PHARMACOLOGIC PRINCIPLES GOVERNING TCI
In anesthesia practice, bolus doses are typically admin-
istered in units of milligrams or micrograms. If doses are 
adjusted for weight, then the dose will be milligrams per 
kilogram or micrograms per kilogram. Infusion rates are 
similarly set in units of milligrams per minute or micro-
grams per minute. If the infusion is weight based, then the 
Target-controlled infusion (TCI) is a technique of infusing IV drugs to achieve a user-defined 
predicted (“target”) drug concentration in a specific body compartment or tissue of interest. In 
this review, we describe the pharmacokinetic principles of TCI, the development of TCI systems, 
and technical and regulatory issues addressed in prototype development. We also describe the 
launch of the current clinically available systems.  (Anesth Analg 2016;122:56–69)
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rate will be milligrams per kilogram per minute or micro-
grams per kilogram per minute.
TCI systems use a different approach. Rather than setting the 
drug administration rate, the user sets a target concentration to 
achieve a user-defined predicted drug concentration in a specific 
body compartment or tissue of interest. Anesthesiologists find 
this intuitive, because it is exactly how we administer inhaled 
anesthetics. The analogy to dosing inhaled anesthetics is strong. 
We often think of end-tidal inhaled anesthetics, but we real-
ize that the target organ is the brain. End-tidal concentrations 
are only interesting because the brain gradually equilibrates 
to the end-tidal concentration. Similarly, TCI systems model 
the plasma drug concentration. However, that is only interest-
ing because the brain gradually equilibrates with the plasma. 
Anesthesiologists may initially administer inhaled anesthet-
ics to achieve a higher end-tidal concentration than desired, 
by using the overpressure to accelerate the onset of drug effect 
in the brain. As will be described, contemporary TCI systems 
can be instructed to overshoot the desired concentration in the 
plasma to accelerate the rate of onset of drug effect. It turns out 
that this approach matches what we do clinically when we first 
administer a bolus followed by a continuous infusion.11
The fundamental characteristic of TCI systems is incor-
porating tissue drug concentrations into the calculations of 
the infusion rate required to achieve the target concentra-
tion. Because tissue drug concentrations cannot be mea-
sured in real time for IV anesthetic drugs, the computer uses 
a PK–pharmacodynamic (PD) model to estimate the con-
centrations. With this information, the computer calculates 
the infusion rate required to reach and maintain a specific 
predicted plasma or effect-site concentration.
Thus, an anesthesiologist using a TCI system to admin-
ister an IV agent is able to set and change a target con-
centration, basing the choice of target concentration on 
observation of clinical effect. Multicompartment PK–PD 
models are used by TCI systems to calculate the infusion 
rates required to reach and maintain the target concentra-
tion. A computer or microprocessor is required to perform 
the calculations and control the infusion pump.
TCI systems target a concentration in the plasma or at the 
site of drug effect. The basic mathematics is surprisingly triv-
ial. Let’s say that you have a box full with 100 kg of chocolate. 
Every 10 minutes, you remove 1% of the chocolate from the 
box. Figure 1A depicts this setting. After 10 minutes, there 
would be 99 kg of chocolate in the box. Ten minutes later, 
there would be 98.01 kg (99 − 99 × 0.01). Ten minutes later, 
there would be 97.03 kg (98.01 − 98.01 × 0.01). Repeating this 
process (e.g., with a spreadsheet): after 4 hours, there would 
be 78.5 kg; after 1 day, there would be 23.5 kg; after 2 days, 
there would be 5.5 kg; and after a week, just 0.004 kg. The 
decline in chocolate over time is shown in Figure 1B.
Let’s consider a slightly different scenario. Rather than eat-
ing the chocolate, you put it in another box. As the first box 
loses chocolate, the second box gains chocolate. Nearly all of 
the chocolate will eventually be in the second box. However, 
what happens if you apply this same rule to the second box, 
returning the chocolate to the first box? The scenario is shown 
in Figure 1C. What happens is that as the chocolate increases 
in the second box, some of it starts returning to the first box, 
because the process is symmetrical. Eventually you reach 
steady state, where each box has 50 kg of chocolate. This is 
shown in Figure  1D. Things are still happening at steady 
state. Specifically, every 10 minutes you still transfer 0.5 kg 
of chocolate (1%) from box 1 to box 2. However, because it is 
symmetrical, you also transfer 0.5 kg of chocolate from box 2 
to box 1, so there is no net change in either box.
We can reduce this to an equation by simply saying what 
the transfer rule is for each box. The equation will take the 




Figure 1. The chocolate model. A, A box full with 100 kg of chocolate where you remove 1% of the chocolate every 10 minutes. B, The decline 
of the chocolate in the box shown in (A). C, A scenario where you start with a full box 1 and an empty box 2. You transfer 1% of the chocolate 
every 10 minutes from box 1 in box 2 and you return the same amount every 10 minutes from box 2 to box 1, finally creating a steady-state 
situation in which a same amount is transferred per time between both boxes. D, The changes in chocolate amount in both boxes in time.
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Change in chocolate in box 1
Chocolate in box 2  1  . –
=
× 0 0 Chocolate in box 1  1× 0 0.
Change in chocolate box 2 
Chocolate in box 1  1 Chocol
=
× 0 0. − ate in box 2  1× 0 0.
We will replace “change in” by the mathematical sym-
bol Δ. We will replace chocolate in box 1 by “C1” and choc-
olate in box 2 by “C2,” and we will obtain the following 
equations:
∆C C 1  C  11 2 1= × ×0 0 0 0. .−
∆C C  1 C  12 1 2= × ×0 0 0 0. .−
Let’s now label the rate of transfer from box 1 to box 2 as 
K12, and the rate of transfer from box 2 to box 1 as K21. The 
chocolate transferring equation can be reduced to:
∆C C K  C K1 2 21 1 12= –
∆C C K  C K2 1 12 2 21= –
These are called difference equations. They are a simpli-
fied manner of representing differential equations. Figure 2 
shows the PK model that is used for nearly all IV drugs, 
including the time delay between the plasma and the site of 
drug effect (e.g., the brain).12,13 Because there are more boxes, 
the PK model requires more housekeeping than the choco-
late model. Other than the requirement for more housekeep-
ing, the model is exactly the same. Let’s call the amount of 
drug in compartments 1, 2, 3, and the effect site as A1, A2, A3, 
and Ae, respectively. The difference equations are as follows:
∆A A K  A K A K A K A K Drug input1 2 21 3 31 1 1 1 12 1 13= + +– – –0
∆A A K  A K2 1 12 2 21= –
∆A A K  A K3 3 13 3 31= –
DA  A K  A Ke 1 1e e e= – 0
This is all the computer needs to do to track the concen-
trations of drug in all 4 compartments. It is literally trivial. 
The difference equations are simplified versions of the dif-
ferential equations:
dA t dt I t k A t k A t
k A t k k k k
1 21 2 31 3
e 4 1 12 13
( ) = ( ) + ( ) + ( )
+ ( ) − + + +
/ · ·
·0 0 1e 1A t( ) ( )· s
dA t dt k A t   k A t2 12 1 21 2( ) = ( ) − ( )/ · ·
dA t dt k A t   k A t3 13 1 31 3( ) = ( ) − ( )/ · ·
dA t dt k A t   k A te 1e 1 e e( ) = ( ) − ( )/ · ·0
The difference equations describe the rate of transfer 
over a small slice of time, whereas the differential equations 
describe the instantaneous rate of transfer at time t. As a tech-
nical detail, in the differential equations, the units of k are 1/
time. This is because Δ time appears in the equation (dt). Time 
cancels out when k is multiplied by dt. When the value of k in 
the differential equations is multiplied by the time slice (e.g., 
10 minutes), the result is the value of K in difference equa-
tion, which is a unitless fraction (e.g., 1%). For human PKs, 
difference equations using a time interval of 1 second almost 
perfectly match the exact closed-form implementations of the 
differential equations.14 Even the most basic microprocessor 
can manage 4 calculations per second. This approach to solv-
ing differential equations by reducing them to simple differ-
ence equations is called the Euler method, named after the 
Swiss mathematician who proposed it 300 years ago.a
Historically, multiple representations of multiple com-
partmental PK models have been proposed. These are sim-
ply different representations of the model shown in Figure 1. 
Engineers view these models as linear systems.15 This means 
that when you double the dose, you double the concentra-
tions over time. Figure 3A shows the same model as a sum 
of exponentials. Figure 3B shows an hydraulic model com-
posed of tanks (volumes of distribution) connected by pipes 
(clearances). The tank marked “V1” is the plasma compart-
ment. The tanks and pipes are mathematical transformations 
of the model in Figure 2.16,17 PK compartment models have 
been developed for nearly all IV drugs in anesthesia.9,18–27
The classical PK model for anesthetic drugs is a 2- or 
3- compartment model. The models account for the delay 
between the plasma concentration and the drug effect by 
adding an effect-site compartment (Fig. 2).12,28 The delay in 
equilibration between the plasma and the effect compart-
ment concentrations is mathematically described by a single 
parameter, defined as ke0, the effect-site equilibration rate 
constant.29 The value of ke0 can be determined from com-
plex PK/PD studies combining blood concentrations with 
frequent measurements of drug effect.30 It is also possible to 
calculate ke0 from the directly observed time to peak effect 
after a bolus injection.17,31,32
MANAGING THE INFUSION SCHEMES DURING TCI
The first practical TCI implementation used the bolus elimi-
nation transfer (BET) approach. First, a bolus of drug is 
given, calculated as the target plasma concentration times 
Figure 2. The 3-compartmental model, with 3 volumes of distri-
bution (V1, V2, and V3) and various k values representing the rate 
and direction of movement of the drug among the compartments 
(k12, k21, k13, and k31) or toward the outside (k10). Drug is adminis-
tered into a central compartment, from which it is eliminated. Drug 
is rapidly and slowly distributed in a second and a third compart-
ment, respectively. The 3-compartmental model is enlarged with 
a pharmacodynamic effect-site compartment, governing the time 
delay between the plasma concentration and the clinical drug effect 
(represented by ke0). ahttps://en.wikipedia.org/wiki/Leonhard_Euler. Accessed July 15, 2015.
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the initial distribution volume. This bolus theoretically 
instantly produces the target plasma concentration. Second, 
a maintenance infusion equal to the elimination rate is given. 
The maintenance infusion rate is simply the target plasma 
concentration times the systemic clearance. Were it not for 
drug accumulation into the peripheral compartments, this 
simple bolus and infusion approach would maintain a con-
stant drug concentration. Unfortunately, it does not work 
for any IV drugs used by anesthesiologists, because all our 
drugs accumulate over time in peripheral tissues.
A third infusion is required to replace drug transferred 
from the plasma to peripheral compartments. As the com-
partments come into equilibrium with the central (plasma) 
compartment, the amount of drug transferred to peripheral 
tissues declines exponentially. As a result, this third trans-
fer infusion decreases exponentially, reaching 0 when the 
compartments are all in equilibrium (i.e., at the same con-
centration).7 The infusion rate is the desired concentration × 
K t t12 1322 31e K e
K K− −+ . Because it is relatively straightforward to 
calculate using a spreadsheet, the BET scheme is still being 
used to develop dosing guidelines. However, the BET infu-
sion scheme has 2 major drawbacks. First, it can only be 
used to target the plasma concentration. Researchers recog-
nized that targeting the effect site would result in a better 
infusion strategy that more closely matches the desired time 
course of drug effect,11 but this required an extension of this 
PK model. Second, the BET scheme is only applicable in the 
absence of drug previously administered. The BET scheme 
cannot be used if the intent is to titrate the drug-to-drug 
effect. This limitation led investigators to replace BET with 
a more flexible approach to TCI administration.2,33
As reviewed later, in the mid-1980s and early 1990s, 
various research groups developed algorithms to titrate 
plasma or effect-site concentrations.14,34,35 A closed-form 
mathematical solution for TCI was published and imple-
mented by Shafer and Gregg,11 Shafer et al.,34 and Jacobs.8 
These approaches precisely tracked drug concentration, but 
the infusion rate was an approximate solution. Jacobs36 first 
described the exactly correct solution in 1990. The following 
year, Bailey and Shafer37 published a simplified algorithm 
that provided exact solutions. This algorithm, extended by 
Shafer and Gregg11 to include the effect site, became the 
basis of all TCI systems.
TCI SOFTWARE PLATFORMS
Historical Prototypes
In 1919, Widmark38 described the kinetics for accumulat-
























Figure 3. A, The log-linear represented 
time course of the plasma concentra-
tion over time observed after a bolus 
of an IV-administered drug. Each com-
ponent term represents a portion of 
the curve. The individual lines associ-
ated with each component term are 
also shown. The triexponential curve 
represents the algebraic sum of the 
individual exponential functions. The 
intercepts of the curve peel are shown 
as A, B, and C. These are present as 
coefficients of the triexponential equa-
tion. B, The 3-compartmental model 
represented as a hydraulic model. The 
width of each tube is proportional to its 
specific volume of distribution (V1, V2, 
and V3) and the height is proportional to 
the concentration. The magnitude of the 
metabolic (Cl1) and intercompartmental 
clearance (Cl2 and Cl3) is depicted by 
the width of the tubes.
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using constant rate and first-order elimination in a drug 
showing single compartmental kinetics. In 1968, Kruger-
Thiemer39 published a mathematical approach for calcu-
lating infusion rates to reach and maintain a steady-state 
blood concentration of a drug described by 2 or more com-
partments. Vaughan and Tucker40,41 applied this model to a 
lidocaine infusion.
Schüttler and Schwilden performed the first TCI admin-
istration in Bonn, Germany, on May 1, 1979. In 1981, 
Schwilden42 published a generalized method for calculat-
ing the dosage schemes in linear kinetics. Two years later, 
Schüttler, Schwilden, and Stoeckel published their first 
clinical experience with the CATIA system, the first practi-
cal TCI system (Fig. 4). They described the use of the BET 
scheme in a plasma-targeted TCI of etomidate (0.3 μg/mL) 
and alfentanil (0.45 μg/mL) to induce and maintain anes-
thesia. They concluded that CATIA provided adequate drug 
effect during anesthesia with a short recovery period.43,44 In 
1985, the Bonn group used CATIA to study the cerebral PDs 
of etomidate during linearly increasing predicted plasma 
concentrations of etomidate, the first use of TCI drug 
administration to quantify drug effects.45,46 In 1988, the same 
group enhanced their software to administer propofol and 
alfentanil. They demonstrated that TCI provided a smooth 
induction without significant hemodynamic alterations, by 
good intraoperative titration, and rapid recovery.6
In Leiden, the Netherlands, Ausems and Hug47 and 
Ausems et al.48 were studying alfentanil PKs. Inspired by 
the work from the Bonn group, and supported by Janssen 
Pharmaceutica (Beerse, Belgium), they used a developed 
TIAC to evaluate the accuracy of their alfentanil model dur-
ing plasma-controlled TCI. They documented intersubject 
variability between measured and predicted concentrations 
between 22% and 32%, which is typical of alfentanil PKs, 
and concluded that TCI can be used to rapidly attain a rela-
tively stable plasma concentration and to facilitate titration 
to the requirements of an individual patient during anesthe-
sia.49 In 1988, the Leiden group used their alfentanil model 
to predict plasma concentrations during repeated bolus and 
variable rate infusions. The variability was similar to that 
of their TCI studies, demonstrating that PK variability has 
nothing to do with the infusion methodology but reflects 
the underlying biology.50 In an additional study compar-
ing plasma-controlled TCI administration of alfentanil with 
repeated bolus injections, Ausems et al. found that repeated 
bolus injections resulted in rapid fluctuations in alfentanil 
concentrations, which were not seen with TCI adminis-
tration, an expected result. Although both methods con-
trolled the patients’ responses to noxious stimuli, the TCI 
group found a lower incidence of responsiveness, greater 
hemodynamic stability, and a somewhat lower incidence 
of side effects. They also used TCI as a tool to precisely 
quantify alfentanil concentration versus anesthetic effect 
relationships.51
Other groups were inspired by the research from Bonn 
and Leiden. In Bristol, United Kingdom, Tackley et al. devel-
oped a propofol TCI system using the BET approach based 
on the previously derived PKs from a propofol single-bolus 
study.52 They found that blood concentrations were close to 
the predicted target.7 A decade later, they incorporated ket-
amine into the device.53
As a visiting professor in Bonn in the early 1980s, Reves 
saw the work of Schüttler and Schwilden. On returning to 
the University of Alabama, Reves and Alvis developed 
CACI, a TCI system to titrate fentanyl and sufentanil dur-
ing cardiac surgery.35,54 CACI was written in PASCAL and 
was implemented on an Apple II Plus® computer (Apple, 
Cupertino, CA) that controlled an IMED 929® infusion pump 
(Carefusion, Basingstoke, UK). They applied a numerical 
approximation using a bilinear Z-transform of the differential 
equations.35 This approach allowed approximate adjustment 
of the targeted plasma concentrations during infusion, which 
was not possible with the BET approach. Reves moved to 
Duke University and developed the CACI II system together 
with Jacobs (Fig. 4). This device consisted of a Datavue model 
25 microcomputer connected to Abbott LifeCare model 4 
infusion pumps. CACI II was programmed with PK mod-
els for fentanyl, alfentanil, sufentanil, midazolam, and pro-
pofol.36,55 CACI II incorporated an enhanced algorithm for 
optimal linear-based control of the plasma concentration, 
developed by Jacobs.36 Reves and coworkers used the CACI 
II prototype for many years in the late 1980s and 1990s at 
Duke University Medical Center, particularly to administer 
midazolam and fentanyl in cardiac surgery patients (Jerry 
Reves, MD, May 12, 2014, personal communication).
Figure 4. Top, Computer-assisted total IV anesthesia system (pho-
tograph courtesy of J. Schüttler, MD, Erlangen, Germany); Bottom, 
Computer-assisted continuous infusion II system using a Datavue 
25 computer connected to an Abbott LifeCare pump Model 4 (photo-
graph courtesy of T. Egan, MD, Utah).
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Don Stanski was similarly influenced by a sabbatical in 
Leiden, where he collaborated with Ausems and Lemmens 
in the TIAC studies. On returning to Stanford, Stanski 
recruited Steve Shafer to study PKs and specifically to 
investigate TCI. Shafer et al.34 first evaluated the accuracy of 
the CACI I device and found various limitations. Unable to 
use CACI II, Shafer developed STANPUMP (for STANford 
PUMP), written in C. STANPUMP was intended to be a 
generic program, and ran on any MS DOS-based computer. 
STANPUMP supported multiple infusion pumps, includ-
ing the IMED 929, IMED C2 protocol, BARD Chronofusor, 
Harvard Pump 22, and the Graseby 3400 infusion pumps 
(Fig. 5). Initial versions of STANPUMP used Euler linear 
approximate of the differential equations (the approach 
used to transfer chocolates between boxes described ear-
lier). The final version of STANPUMP uses an analytical 
solution to the 3-compartmental model to control plasma 
concentrations using TCI.37 After 1993, the authors included 
the algorithms to rapidly achieve and maintain stable drug 
concentrations at the effect-site level allowing effect com-
partment-controlled TCI.11 Effect-site control was a major 
step in providing precise titration of anesthetic drug effect. 
STANPUMP served as a testing environment for the imple-
mentation of other PK/PD principles, including application 
of the “Tpeak approach” to combining PK data from one 
study with PD data from another study,31 the implementa-
tion of a maximum a posteriori probability Bayesian update 
of PK/PD parameters in real time from observations during 
drug administration,56 the creation of detailed output files 
that could be directly incorporated into PK/PD estimating 
programs, the ability to read external files to use the PKs of 
any drugs, accommodation of multiple syringe sizes, and 
the ability to run from batch files, and command line-driven 
batch mode to facilitate clinical research (Steven L. Shafer, 
MD, June 5, 2014, personal communication). STANPUMP’s 
PK/PD drug library contains models propofol, thiopental, 
methohexital, ketamine, etomidate, fentanyl, alfentanil, suf-
entanil, remifentanil, midazolam, diazepam, lorazepam, 
lidocaine, ketamine, rocuronium, vecuronium, atracurium, 
and pancuronium. As a research tool, it also has PKs for 
dogs, rats, horses, as well as humans. Shafer freely dis-
tributed STANPUMP, which explains why nearly half of 
the 559 studies in Appendix 1 of our accompanying article 
were conducted using STANPUMP.4 Many of the principles 
implemented in STANPUMP, and even the code for the PK 
engine, were incorporated into subsequent implementa-
tions of research TCI systems and the commercially avail-
able Open TCI devices (Steven L. Shafer, MD, 2014, personal 
communication).
In Leiden, Jim Bovill continued the opioid pharmacology 
research conducted by Ausems. Because the TIAC device 
only allowed a 2 compartments, a new device was required 
for further research. Frank Engbers at Leiden University 
developed several TCI systems in the early 1990s. His first 
system used PC-based software connected to an IMED 929 
and programmed in Turbo Pascal. This system was followed 
by a portable system comprising an Atari Portfolio palm-
top computer driving 2 Ohmeda 9000 pumps and could 
be used to administer 2 drugs in TCI mode. These devices 
were used to study PD drug interactions.57 This version was 
then followed by another portable system using a Psion 
3A controlling 2 Fresenius or Graseby pumps (Fig. 6). The 
software was written in OPL and C. This system could do 
effect compartment-controlled TCI for only 1 pump because 
Figure 5. Top, The STANPUMP TCI system using an MS-DOS-based 
PC connected to a Harvard Apparatus syringe pump (photograph 
courtesy of S. L. Shafer, MD, Stanford, CA). Bottom, Screenshot of 
the STELPUMP dual channel TCI system (photograph courtesy of J. 
Coetzee, MD, Stellenbosch, South Africa).
Figure 6. The Leiden target-controlled infusion system connected to 
2 Fresenius syringe pumps (photograph courtesy of F. Engbers, MD, 
Leiden, The Netherlands).
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of limited capacity of the processor. The investigators fur-
ther adopted this system TCI-patient-controlled-analgesia 
of alfentanil for postoperative pain with a safety loop back 
function using a respiration monitor.58 One system is still in 
use at the authors’ institution (Frank Engbers, MD, Leiden, 
March 4, 2014, personal communication).
At Glasgow University, White and Kenny developed an 
Atari-controlled propofol computer pump to deliver a specific 
targeted plasma concentration of propofol.59 Roberts et al.60 at 
Bristol suggested that 3 μg/mL was the right concentration for 
propofol.61 They developed their own TCI prototype60 using 
an Ohmeda 9000 pump connected to a Psion Organiser hand-
held computer.62 Later the Psion organizer was replaced by a 
customized backbar containing a dual microprocessor con-
trol system and served as the prototype for the Diprifusor™ 
module (AstraZeneca, London, UK), the first commercial TCI 
device (see paragraph on Introduction of the Diprifusor). The 
Diprifusor module used 2 processors to solve the PK equations. 
The 8-bit processor used an Euler approximation for a parallel 
calculation of plasma concentration based on the movement of 
the motor, but the 16-bit processor uses a more complex algo-
rithm. This was done to ensure a double check on the infused 
volume to guarantee safety. Because this was to be the first com-
mercial implementation of a microprocessor infusion device, it 
was anticipated that regulatory authorities would be reassured 
by the presence of a second independent checking processor.
In the early 1990s, Johan Coetzee and Ralph Pina from 
Stellenbosch University, South Africa, developed STELPUMP 
(STELlenbosch PUMP), a TCI platform written in Borland’s 
Turbo Pascal for MS DOS (Fig. 5). STELPUMP uses the Euler 
method’s numerical approximation method to derive the 
plasma concentration34 and the algorithm from Jacobs and 
Williams63 to calculate the effect-site concentration. STELPUMP 
can control 2 syringe pumps simultaneously and is connect-
able to various syringe pumps such as the B. Braun Perfusor 
Secura pump, Harvard 22 syringe pump, Graseby 3400, and 
IVAC P4000. STELPUMP was one of the first programs offer-
ing a graphic interface. STELPUMP permitted users to specify 
PK parameter sets, maximum permissible plasma concentra-
tion (particularly important during effect-site targeted TCI), 
syringes brand and size, drug concentration, and infusion 
units. The data files from STELPUMP can be imported to a 
spreadsheet for graphing, etc. Coetzee made STELPUMP freely 
available for researchers. It has been used in various pharma-
cology studies4 (Johan Coetzee, MD, March 21, 2014). As shown 
in Appendix 1 of the companion article,4 STELPUMP has been 
particularly extensively used for studies in Asia.
Following the example of STANPUMP and STELPUMP, 
De Smet and Struys developed a modular computer-based 
TCI software called RUGLOOP (Fig. 7), written in C++ 
for Windows. The name RUGLOOP is a concatenation of 
Rijksuniversiteit Gent, the Flemish name of the University of 
Ghent, and“loop”, as the system also served as the engine 
for their closed-loop drug administration system. RUGLOOP 
continues the tradition of STANPUMP and STELPUMP in 
being named for their host universities. The current release, 
RUGLOOP II is able to control multiple-syringe pumps simul-
taneously administering multiple drugs, targeting either the 
plasma or effect-site concentration. RUGLOOP II integrates 
the TCI software in a software platform capable of collecting 
vital signs from various monitors during research projects. 
RUGLOOP II uses analytically solved PK/PD algorithms 
similar to that of STANPUMP to calculate target plasma and 
effect-site concentration. In addition, RUGLOOP II serves as 
the engine for the closed-loop system for propofol adminis-
tration using the bispectral index as a controlled variable.64,65 
RUGLOOP II also allows TCI-patient-controlled analgesia 
and TCI-patient-controlled sedation.66 It is still actively used 
in research projects.4
Other research groups developed Windows-based, mul-
tichannel TCI software packages. In Erlangen, the pioneer-
ing group of Schüttler and Schwilden developed IVFEED 
(Fig. 7) allowing both plasma and effect-site TCI for multiple 
drugs. IVFEED uses the iterative analytical algorithm devel-
oped by Bailey and Shafer37 to control the plasma concen-
tration and an iterative analytical algorithm with forecasting 
similar to that described by Jacobs and Williams.63 Aside 
from being able to maintain a specific target plasma or effect-
site concentration, IVFEED can control a linearly increasing 
target concentration. The newest version of IVFEED allows 
TCI-patient-controlled analgesia. In 1999, researchers at 
the Facultad de Medicina Universidad de Chili developed 
AnestFusor using control plasma and effect-site concentra-
tions during TCI (Fig. 8). AnestFusor has an extended drug 
library and can be connected to various syringe pumps. 
AnestFusor has been commercialized as ezFUSOR in Chili. 
More information can be found at http://www.smb.cl/
ezFusor/indexen.html. Barvais and coworkers in Brussels, 
Belgium, developed various TCI software platforms over the 
past 25 years. The most recent version of their TCI software 
is called TOOLBOX (Fig. 8). Like RUGLOOP, TOOLBOX is a 
Windows program that can capture information from physi-
ologic monitors, can perform closed-loop control based on 
the feedback from the monitors, and can control various 
commercially available infusion pumps.
INTRODUCTION OF THE DIPRIFUSOR TCI SYSTEM 
(EXCEPT IN UNITED STATES)
Propofol was launched in Europe in 1986. It was immedi-
ately apparent that propofol could be given by repeated 
injection or continuous infusion to maintain anesthesia, 
without incuring the long recovery seen with thiopental, the 
other IV-available hypnotic. A number of manually adjusted 
step-down infusion schemes for propofol infusion, generally 
in combination with an opioid analgesic or regional anesthe-
sia, were described and achieved satisfactory results.60,67,68 In 
1990, the research department at ICI Pharmaceuticals hosted 
a meeting of the international groups who had developed 
research TCI systems (described earlier) to consider the 
possibility of commercializing TCI development. That pre-
liminary meeting, coupled with a TCI symposium at the 
1992 World Congress of Anaesthesiology in The Hague, 
convinced ICI that TCI could facilitate the use of propo-
fol for maintenance of anesthesia. The development of the 
Diprifusor TCI system and associated technology has been 
described elsewhere69–71 but will be summarized briefly 
here. Zenecab decided not to manufacture TCI devices but 
rather to support independent medical devices compa-
nies interested in commercializing TCI technology. TCI is a 
bThe pharmaceuticals and agrochemicals divisions of ICI were divested as 
Zeneca from the parent company in 1992.
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drug-device combination, an uncommon application for reg-
ulatory authorities. The regulatory strategy was developed 
in discussions with regulatory authorities and interested 
device manufacturers. To ensure a standardized approach 
by different companies, ICI developed an electronics mod-
ule incorporating one of several available PK models20 and 
infusion control software. The use of the Diprifusor module 
ensured standardized drug delivery for any TCI device. The 
PK model was selected based on the computer simulation 
studies,69 a prospective comparative study of 3 models,72 and 
discussions with academic groups. The Diprifusor control 
algorithms were developed by White and Kenny.59 The con-
trol system used 2 microprocessors. The main 16-bit micro-
processor implemented an exact mathematical solution, 
whereas the 8-bit microprocessor implemented a numerical 
approximate (the Euler method’s solution, illustrated with 
the aforementioned chocolate model) to independently 
check the calculations.70 The Glasgow group had significant 
clinical experience with this system, supplemented with 8 
additional clinical trials in 428 patients sponsored by Zeneca 
to document the safety and efficacy of propofol adminis-
tration by TCI. The studies also determined appropriate 
plasma-target settings for induction and maintenance of 
anesthesia, which were incorporated into the propofol label. 
Patients included in the program ranged in age from 16 to 83 
years, with a weight ranging from 36 to 123 kg, ASA physical 
status I to III, undergoing gynecologic or orthopedic surgery, 
or major procedures expected to last for 3 to 6 hours, includ-
ing major head and neck, abdominal, and neurosurgical 
procedures. Two studies involved patients undergoing coro-
nary artery surgery. Efficacy assessments included induc-
tion times, hemodynamic effects, quality of anesthesia, and 
recovery times. Safety was assessed based on the frequency 
of reported side effects, which were consistent with previous 
experience with propofol.
Based on the studies, the propofol (Diprivan™, 
AstraZeneca) label was altered to include administration 
of propofol with a Diprifusor TCI system. The label also 
warned against TCI in children, based on the likelihood that 
adult PKs would poorly describe children.
Figure 7. Top, Screenshot from RUGLOOP 
II (photograph courtesy of Tom De Smet, 
PhD, Temse, Belgium). Bottom, IV Feed 
TCI system connected to 2 B. Braun 
Perfusor syringe pumps (photograph 
courtesy of J. Schüttler, MD, Erlangen, 
Germany).
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The Diprifusor module requires the use of electroni-
cally tagged prefilled syringes containing propofol 1% or 
2% injection. This prevents administration of other drugs 
or infusing the wrong concentration of propofol. Because 
propofol (Diprivan) labeling indicates that propofol may be 
administered by TCI only with a Diprifusor system, a con-
sequence is that product labeling for generic preparations 
of propofol does not provide guidance on administration of 
the drug by TCI.
The addition of TCI guidance to the prescribing infor-
mation for Diprivan was approved in the United Kingdom, 
Austria, Norway, Spain, and Sweden in 1996. By the time 
of the Japanese submission in 1999 (approved 2001), fur-
ther approvals had been obtained in Belgium, Brazil, 
Denmark, Eire, Finland, France, Germany, Greece, Holland, 
Luxembourg, Mexico, New Zealand, Portugal, Switzerland, 
and Venezuela. Currently, approvals for TCI administration 
using the Diprifusor module have been granted in >50 
countries. A recent modification of the Diprifusor module 
to provide effect control with a ke0 of 0.6/min has been 
approved, but to date, amended labeling for this use has 
been obtained only in Germany.
Zeneca developed a comprehensive regulatory strategy to 
develop and commercialized the Diprifusor TCI system. In 
Europe, amended labeling for propofol was approved as a 
variation to the marketing authorization for propofol, sub-
ject to the approval of the Diprifusor TCI module and pumps 
incorporating the Diprifusor TCI module by a Notified Body 
acting under the auspices of the European Council directive 
93/42/EEC concerning medical devices who granted a con-
formité européenne (CE) mark of conformity in 1996. The lat-
ter required Zeneca to complete a comprehensive program 
of TCI module software validation and to provide infusion 
pump companies with an integrated Diprivan TCI pump 
Figure 8. Top, Screenshot from AnestFusor 
(photograph courtesy of Andres Stutzin, 
Kristian Brinckmann, and Rodrigo Munoz, 
Santiago, Chili). Bottom, Toolbox software 
running on a laptop, steering multiple 
Fresenius pumps (photograph courtesy of 
L. Barvais, MD, Brussels, Belgium).
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specification. Compliance with this specification ensured that 
all devices incorporating the Diprifusor TCI module would 
deliver propofol in a standard manner, specified as a precise 
infusion profile for specified target plasma propofol concen-
trations. The first CE marking for an infusion pump contain-
ing the Diprifusor TCI module was obtained in 1996 by Vial 
Medical, later acquired by Fresenius.
By 1997, the Diprifusor module had been incorporated in 
the Graseby 3500 syringe pump (Smiths Medical, Ashford, 
United Kingdom), the Alaris IVAC P6000 TCI pump 
(Carefusion, Basingstoke, United Kingdom), the Fresenius 
Master TCI pump (Fresenius, Bresins, France), and (later) the 
Terumo TE-372 syringe pump (Terumo, Tokyo, Japan; Fig. 9).
Zeneca sponsored local TCI courses to provide train-
ing TCI by local and international experts. These meetings 
involved lectures, including live video links to an operat-
ing theater where a Diprifusor TCI system was being used, 
and hands-on training with an infusion pump. The train-
ing included providing Diprifusor TCI systems to hospitals, 
analogous to the introduction of new inhaled agents by pro-
viding interested clinicians with calibrated vaporizers. Most 
of these pumps are still used clinically in various countries.
Two aspects of the Diprifusor TCI systems limited their 
continued acceptance. First, there was no ability to control 
the concentration at the site of drug effect. This reflected the 
introduction of effect-site control11 after the basic design of 
the Diprifusor module had been settled.59 The Diprifusor TCI 
systems could only administer Diprivan-branded propofol. 
Once generic propofol became available, clinicians wanted 
open TCI systems that could administer generic propofol, 
as well as other drugs (particularly remifentanil). Clinicians 
also wanted the additional precision of controlling the drug 
concentration at the site of drug effect. Gradually open TCI 
systems replaced Diprifusor TCI system in most countries. 
However, as the pioneering TCI platform, the Diprifusor 
TCI system and accompanying training program intro-
duced TCI to routine clinical practice worldwide.
REGULATORY ODESSEY OF THE DIPRIFUSOR TCI 
SYSTEM IN THE UNITED STATES
In the United States, discussions with the Food and Drug 
Administration (FDA) began in 1993 when a blinded com-
parative study between standard infusions and TCI sys-
tems was requested by the agency. From the beginning, it 
was clear that the FDA was struggling to decide whether 
TCI should be handled by the drug division (the Center 
for Drug Evaluation and Research) or the device division 
(CDRH [the Center for Devices and Radiological Health]). 
The requested study was performed in the United States 
and aimed to compare induction time and the relative sta-
bility of hemodynamics and plasma propofol concentra-
tions with TCI and a manually controlled infusion during 
induction and early maintenance in adult patients under-
going cardiac surgery. The study was a part of the submis-
sion report to the FDA but was not published as a scientific 
paper. Anesthesia was induced more rapidly in the TCI 
group. There was no difference between groups in the vari-
ability of measured plasma propofol concentrations and no 
clinically relevant differences in hemodynamic responses 
or safety assessments. These data were submitted with the 
European clinical and module validation data to support a 
Premarket Approval Application (PMA) to CDRH in 1995, 
followed by a PMA amendment demonstrating compliance 
of the Graseby 3500 pump incorporating the Diprifusor 
module with Zeneca’s delivery performance specification. 
A prefilled syringe presentation of propofol had been pro-
duced. The FDA supported the proposal of Zeneca to use an 
electronic tag to confirm the presence and concentration of 
propofol in the syringe.
In 1996, the reviewers at the FDA changed, and the sub-
mission was transferred to Center for Drug Evaluation 
and Research as a supplement to the Diprivan New Drug 
Application, to be accompanied by approval of the Graseby 
pump incorporating a Diprifusor TCI module as a 510k 
Application (demonstration of equivalence) submitted to 
Figure 9. Target-controlled infusion (TCI) pumps incorporating the Diprifusor module: Graseby 3500 syringe pump (Smiths Medical, Ashford, 
United Kingdom), Alaris IVAC P6000 TCI pump (Carefusion, Basingstoke, United Kingdom), Fresenius Master TCI pump (Fresenius, Bresins, 
France), and Terumo TE-372 syringe (Terumo, Tokyo, Japan; with permission from companies).
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CDRH. The FDA sent Zeneca an approvable letter in 1997, 
but with an unacceptable requirement. Concerned about PK 
variability, the letter stated that the control dial for the pump 
be marked in ranges of 0.5 to 4, 1 to 8, and 2 to 16 μg/mL to 
reflect PK variability. This implied, incorrectly, that the TCI 
pump was somehow responsible for PK variability. The fol-
lowing year the FDA accepted that this was an impractical 
approach and agreed that a label should simply point out 
that the actual plasma concentration differed from the target 
concentration because of PK variability. Additional safety 
updates and training plans were requested by the FDA, and 
answers were provided by Zeneca.
In 2000, the reviewers at the FDA changed again. The new 
team disagreed with earlier completed reviews. In 2001, the 
FDA issued a nonapprovable letter, considering the lack of 
precision in dosing posed an unacceptable risk. This occurred 
despite the concurrent extensive use of Diprifusor systems 
outside of the United States with no safety concerns. Assigning 
“blame” for PK variability to the TCI system, the FDA required 
a redesign of the TCI system. The FDA also requested further 
clinical trials to evaluate safety. In 2002, AstraZenecac provided 
a response explaining that occasional outlying values of mea-
sured blood concentration were a consequence of PK variabil-
ity and had not been associated with adverse events. Because 
the FDA had requested, Graseby submitted a 510k application 
for their TCI device. The FDA responded that there was no 
equivalent device marketed in the United States, upon which 
Graseby withdrew their 510K application.
By 2002, generic propofol was appearing in the market. 
The delays in FDA approval caused medical device compa-
nies to pursue open TCI systems for use outside of the United 
States. AstraZeneca was unwilling to initiate further clinical 
work with the Diprifusor TCI system in the United States. 
The New Drug Application submission was withdrawn in 
2004, 9 years after initial submission to the FDA. In retro-
spect, the initial strategy suggested by the FDA that Zeneca 
pursue a PMA route would have been the most appropriate.
As long as the FDA insisted that TCI systems eliminate 
PK variability, an expectation not made of any other form of 
drug delivery, TCI had no path forward in the United States. 
Looking ahead, the mathematical proof that TCI systems nec-
essarily have less variability than bolus injection1 may open 
a path to approval of TCI systems in the United States not 
unnecessarily encumbered by the reality of PK variability.
OPEN TCI SYSTEMS
Starting in 2002, medical device companies introduced open 
TCI systems. In contrast to Diprifusor TCI systems, open 
TCI systems were not limited to propofol from one com-
pany. When using open TCI systems, the clinician selected 
a specific drug and a specific PK/PD model from the drug 
library incorporated in the device. Open TCI systems are 
also capable of targeting either plasma or effect compart-
ment control mode. Carefusion (Basingstoke, United 
Kingdom) and Fresenius (Bresins, France) were the first 
companies launching an open TCI pump. Currently, vari-
ous companies have commercialized open TCI systems. 
More details on the specific models and applications are 
described in our accompanying article.4
As with the pioneering Diprifusor TCI systems, the 
introduction of open TCI systems required a detailed reg-
ulatory strategy. A safe and effective product implies the 
product performs its task, with risks to the patient and the 
operator that are both well understood and satisfactorily 
mitigated. To accomplish this, potential hazards (techni-
cal errors, operator mistakes, and clinical hazards) are 
evaluated. Harmonized standards facilitate evaluation. 
Conformance to a standard provides a reference internally 
and to any third party that this part of the task was executed 
appropriately and/or this assembly of the device functions 
properly. The predominant guidelines are IEC60601 cover-
ing the technical aspects, ISO13485 handling the quality of 
design and manufacturing, and ISO14971 dealing with risk 
management.
In Europe, each medical device, including the open TCI 
systems, has to comply to the European medical device 
directive (MDD 93/42/CEE) to carry the mandatory CE 
mark. For all except the least risk-sensitive medical devices, 
MDD requires a notified body (e.g., TUV, LNE-GMed, SGS) 
to assess conformity to the relevant standards of all stages 
from design to postmarketing. This assessment is reason-
ably efficient because of harmonized standards. There is 
alternative mandatory conformity marking for medical 
devices in other parts of the world (e.g., the Pharmaceutical 
Affairs Law in Japan).
In accordance to the aforementioned data, the open TCI 
systems are evaluated both for their technical performance 
and clinical accuracy. The clinical evidence of the applied 
model and the accurate range of plasma and effect-site 
concentration targets relies on publications in the scientific 
literature. Published models have been embedded in the 
pumps for propofol in adults20,25,26,73 and children,27,74 remi-
fentanil,23,24 sufentanil,22 and alfentanil.19,75 More details can 
be found in our accompanying review of TCI global use.4
The technical verification ensures that, on top of the 
MDD requirements for general-purpose infusion pumps 
as mentioned earlier, open TCI systems will apply an infu-
sion profile and predict a concentration sufficiently close 
to what a pure theoretical implementation of the selected 
clinical model would realize. Because the open TCI systems 
are physical devices, this requires extensive evaluation 
and simulation of long-term stability, absolute momentary 
accuracy of the delivered dose, and absence of rounding 
noise-induced oscillations under all clinical situations for 
each model implemented. Pure theoretical implementation 
includes modeling expected PK variability intrinsic to the 
drug and patient population selected.
When the device is commercialized, each company has 
to set up a Plan-Do-Check-Act Quality Insurance System 
using detailed Standard Operating Protocols as described in 
the MDDs to document and categorize all reported device 
errors or clinical complaints. If a serious product perfor-
mance report is filed, a recall or an immediate global update 
of the device can become mandatory. More details can be 
found in our accompanying TCI safety review article.5
Most global or national notified bodies granting mar-
ket approval for the open TCI systems did not request 
cAfter further divestment of the agrochemicals division of Zeneca, the 
remaining Zeneca Pharmaceuticals division of Zeneca merged with Astra to 
form AstraZeneca in 1999.
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additional accuracy studies covering the interpatient vari-
ability in relation to the population model. They considered 
the extensive literature describing PK performance of the 
devices, including that the expected PK variability was 
accurate.1 Neither did they request an update of the drug 
insert labels covering the use of TCI. An exception of the 
above can be found in Japan. A requirement for an altera-
tion in the Diprivan label is the reason that only Diprifusor 
TCI systems are available in Japan today.
In 2008, a Cochrane review by Leslie et al.3 compared TCI 
systems versus manually controlled infusion. The review 
mostly included studies with Diprifusor TCI systems. The 
authors found no significant difference between 2 types of 
anesthetic drug delivery with respect to quality of anesthe-
sia, recovery, or adverse events.
THE FUTURE OF TCI
Future perspectives of TCI are related to model selection 
and optimization, incorporation of more drugs, connectiv-
ity issues with drug advisory displays and anesthesia infor-
mation management systems, integration into closed-loop 
systems, and as a tool to incorporate best practices into peri-
operative medicine. Model optimization using more gener-
ally applicable models might be useful when anesthetizing 
different populations, such as obese patients, children, and 
neonates. These populations were not included in most of the 
original studies generating the values for the current clini-
cally available models. As a result, extrapolations outside the 
original studied population reduce the accuracy of the mod-
els.76 For example, Eleveld et al.77 published a general purpose 
propofol PK model using data made available by various 
research groups. Similar projects should be initiated for other 
drugs in the future, with research funding to support these 
collaborative efforts. Because the various TCI pump manu-
facturers developed their products independently from each 
other using different advisory boards and literature searches, 
the availability of different models for the same IV drugs in 
products from different manufacturers has the potential to 
create confusion for clinicians unfamiliar with the pharma-
cologic principles governing TCI. This experience has limited 
the expansion of the technique despite its clinical benefits.d
Most commercially available open TCI systems include 
models for propofol, fentanyl, sufentanil, alfentanil, and 
remifentanil. Because clinicians are asking for additional 
drugs (e.g., dexmedetomidine, ketamine, and various ben-
zodiazepines) to be added, companies are continuously 
monitoring the possibilities. Hereby, better interaction 
among the pharmaceutical companies, device manufac-
turers, and the device and medicines regulatory agencies 
should be encouraged to provide consistent standards for 
the PK models for the same drug.
Connectivity of medical equipment remains a significant 
problem in anesthesia. Communication protocols between 
open TCI systems and other medical devices should be 
standardized. This will open the possibility to combine 
plasma and effect-site concentration calculated by the TCI 
devices with PD measures such as depth of anesthesia mon-
itors into a single advisory display. Ultimately, this could 
lead to a more general use of closed-loop systems for drug 
administration.17 Finally, standardized real-time reporting 
from TCI devices to anesthesia information management 
systems provides the ability to capture dose and predicted 
concentration. These data can be then used to expand the 
automated safety shell that supplements anesthesiologist 
vigilance with computerized vigilance. Linking TCI drug 
delivery to anesthesia information management systems, 
enhancing the computerized safeguards for anesthesia care, 
may represent the important safety potential of TCI anes-
thetic drug delivery systems. E
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